Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Philippines eyes Sinovac trial as early as November

Published 10/15/2020, 03:14 PM
Updated 10/15/2020, 03:20 PM

MANILA, Oct 15 (Reuters) - Sinovac Biotech SVA.O may start
late-stage trials of its coronavirus vaccine in the Philippines
as early as next month, its food and drugs agency chief said on
Thursday, after it hurdled the initial stage of the country's
screening process.
The Food and Drugs Administration (FDA) expects to receive
the Chinese drug maker's formal application for phase three
clinical trials within two weeks and regulators will make a
decision after their evaluation, FDA head Rolando Enrique
Domingo said.
Domingo told reporters a November trial start was
"possible".
Philippine President Rodrigo Duterte repeated on Wednesday
that he preferred that his country source its COVID-19 vaccines
from either China or Russia.
He also said he wanted the entire population vaccinated and
has previously said he would not reopen schools until a vaccine
was available.
A Sinovac spokesman confirmed that materials had been
provided to the Philippines in the hope of starting Phase 3
trials, but gave no timeframe.
Jaime Montoya, a member of an expert panel screening
applications for clinical trials and medications, told Reuters a
technical evaluation of Sinovac had been completed and results
already submitted to an ethics board for review.
The Philippines is also evaluating COVID-19 vaccines of
Russia's Gamaleya Research Institute and Johnson & Johnson's
Janssen for late-stage trials and is talking to U.S. drugmaker
Pfizer Inc PFE.N and Moderna Inc MRNA.O as potential
suppliers.
The Southeast Asian nation has 346,536 confirmed COVID-19,
the highest in the region, and 6,449 deaths.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.